Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Yu Jin Lim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148.   Published online December 7, 2017
DOI: https://doi.org/10.4143/crt.2017.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.

Citations

Citations to this article as recorded by  
  • Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning
    Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale
    Genes.2023; 14(9): 1768.     CrossRef
  • Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study
    Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
    Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li
    The Breast.2021; 58: 72.     CrossRef
  • Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
    BMC Women's Health.2021;[Epub]     CrossRef
  • Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
    Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias
    The Breast.2021; 60: 255.     CrossRef
  • Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor
    Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He
    Disease Markers.2019; 2019: 1.     CrossRef
  • Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
    Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
    Cancer Research and Treatment.2018; 50(4): 1260.     CrossRef
  • 9,227 View
  • 233 Download
  • 11 Web of Science
  • 7 Crossref
Close layer
Long-Term Outcome of Definitive Radiotherapy for Early Glottic Cancer: Prognostic Factors and Patterns of Local Failure
Yu Jin Lim, Hong-Gyun Wu, Tack-Kyun Kwon, J. Hun Hah, Myung-Whun Sung, Kwang Hyun Kim, Charn Il Park
Cancer Res Treat. 2015;47(4):862-870.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.203
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluates the long-term results of definitive radiotherapy (RT) for early glottic cancer. Clinical and treatment factors related to local control and patterns of failure are analyzed. Materials and Methods We retrospectively reviewed 222 patients with T1-2N0 squamous cell carcinoma of the glottic larynx treated with definitive RT from 1981 to 2010. None of the patients received elective nodal RT or combined chemotherapy. The median total RT dose was 66 Gy. The daily fraction size was < 2.5 Gy in 69% and 2.5 Gy in 31% of patients. The RT field extended from the hyoid bone to the cricoid cartilage.
Results
The median age was 60 years, and 155 patients (70%) had T1 disease. The 5-year rates of local recurrence-free survival (LRFS) and ultimate LRFS with voice preservation were 87.8% and 90.3%, respectively. T2 (hazard ratio [HR], 2.30; 95% confidence interval [CI], 1.08 to 4.94) and anterior commissural involvement (HR, 3.37; 95% CI, 1.62 to 7.02) were significant prognostic factors for LRFS. In 34 patients with local recurrence, tumors recurred in the ipsilateral vocal cord in 28 patients. There were no contralateral vocal cord recurrences. Most acute complications included grade 1-2 dysphagia and/or hoarseness. There was no grade 3 or greater chronic toxicity.
Conclusion
Definitive RT achieved a high cure rate, voice preservation, and tolerable toxicity in early glottic cancer. T2 stage and anterior commissural involvement were prognostic factors for local control. Further optimization of the RT method is needed to reduce the risk of ipsilateral tumor recurrence.

Citations

Citations to this article as recorded by  
  • Superior Regional Control and Laryngeal Function Preservation With Radiotherapy Versus Partial Laryngectomy: A Propensity Score‐Matched Analysis of 562 Early Glottic Cancer Patients
    Shaoqiu Zhang, Ruichen Li, Yang Zhao, Liting Zhu, Ming Guo, Xiaoshen Wang, Yi Zhu
    Head & Neck.2025;[Epub]     CrossRef
  • Dosimetric comparison between carotid-sparing IMRT and 3DCRT in early glottic cancer patients treated with definitive radiation therapy
    Harkirat Kaur, Niketa Thakur, Ramita Sharma, Meena Sudan, Neeraj Jain, Supreet Kaur, Priyanka Lehal
    Journal of Cancer Research and Therapeutics.2024; 20(1): 327.     CrossRef
  • Assessment and validation of glottic motion using cone-beam CT and real-time cine MRI
    Seok-Joo Chun, Jaeman Son, Seonghee Kang, Chang Heon Choi, Jung-in Kim, Young-Il Kim, Joo Ho Lee, Jin Ho Kim, Hong-Gyun Wu
    Strahlentherapie und Onkologie.2024; 200(5): 418.     CrossRef
  • Oncological and Functional Outcomes for Horizontal Glottectomy: A Systematic Review
    Matteo Fermi, Alfredo Lo Manto, Cecilia Lotto, Giulia Cianci, Francesco Mattioli, Daniele Marchioni, Livio Presutti, Ignacio Javier Fernandez
    Journal of Clinical Medicine.2023; 12(6): 2261.     CrossRef
  • Prospective Observational Comparative Study of Response and Toxicities in Early Glottic Cancer Using Telecobalt Versus 3D-CRT
    Sanchayan Mandal, Tamohan Chaudhuri, Dhrubajyoti Mukhopadhyay
    Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 1725.     CrossRef
  • Neck Dissection in Salvage Surgery for Larynx Cancer: National Cancer Database Review
    Tirth R. Patel, Jaijeet Toor, Bobby A. Tajudeen, Mihir Bhayani, Samer Al-Khudari
    Annals of Otology, Rhinology & Laryngology.2022; 131(4): 379.     CrossRef
  • Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
    Tae Hoon Lee, Joo Ho Lee, Seong Keun Kwon, Eun-Jae Chung, Hong-Gyun Wu
    Radiation Oncology Journal.2022; 40(2): 120.     CrossRef
  • Early‐stage vocal cord cancer treated with hypofractionated radiotherapy to the larynx with or without concurrent chemotherapy
    Alexandra N. de Leo, Roi Dagan, Christopher G. Morris, Adam L. Holtzman, Kathryn E. Hitchcock, Curtis M. Bryant, Robert J. Amdur, William M. Mendenhall
    Head & Neck.2022; 44(11): 2513.     CrossRef
  • Long-term impact of smoking cessation on new glottic cancer events in patients with early glottic cancer
    Min-Su Kim, Hong-Gyun Wu, Myung-Whun Sung, Tack-Kyun Kwon
    Acta Otorhinolaryngologica Italica.2022; 42(6): 525.     CrossRef
  • Laser Microsurgery Versus Radiotherapy Versus Open Partial Laryngectomy for T2 Laryngeal Carcinoma: A Systematic Review of Oncological Outcomes
    Flaminia Campo, Jacopo Zocchi, Massimo Ralli, Daniele De Seta, Francesca Yoshie Russo, Diletta Angeletti, Antonio Minni, Antonio Greco, Raul Pellini, Marco de Vincentiis
    Ear, Nose & Throat Journal.2021; 100(1_suppl): 51S.     CrossRef
  • Occult Lymph Node Metastasis in Early‐Stage Glottic Cancer in the National Cancer Database
    Tirth R. Patel, Michael Eggerstedt, Jaijeet Toor, Bobby A. Tajudeen, Inna Husain, Kerstin Stenson, Samer Al‐Khudari
    The Laryngoscope.2021;[Epub]     CrossRef
  • Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer
    N. Patrik Brodin, Rafi Kabarriti, Clyde B. Schechter, Mark Pankuch, Vinai Gondi, Shalom Kalnicki, Madhur K. Garg, Wolfgang A. Tomé
    Radiation Oncology.2021;[Epub]     CrossRef
  • Early glottic cancer recurrence: A critical review on its current management
    Luca Giovanni Locatello, Chiara Bruno, Oreste Gallo
    Critical Reviews in Oncology/Hematology.2021; 160: 103298.     CrossRef
  • TLM Outcomes in Elderly Patients with Glottic Pre-Malignancy and Early Malignancy; A 12-Year Retrospective Study
    Heidi Jones, Elizabeth Ross, Jemy Jose
    Annals of Otology, Rhinology & Laryngology.2021; 130(12): 1392.     CrossRef
  • Prognostic value of the maximum standardized uptake value for the locoregional control in early glottic cancer
    Donghyun Kim, Yongkan Ki, Jihyeon Joo, Hosang Jeon, Dahl Park, Jiho Nam, Wontaek Kim
    Radiation Oncology Journal.2021; 39(4): 297.     CrossRef
  • Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation
    Abdallah S.R. Mohamed, Blaine D. Smith, Joshua B. Smith, Parag Sevak, Jessica S. Malek, Aasheesh Kanwar, Theodora Browne, G. Brandon Gunn, Adam S. Garden, Steven J. Frank, William H. Morrison, Jack Phan, Mark Zafereo, Heath Skinner, Stephen Y. Lai, Kather
    The Laryngoscope.2020; 130(1): 146.     CrossRef
  • Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study
    S. Chatterjee, I. Mallick, S. Chakraborty, S. Prasath, M. Arunsingh, R.B. Achari, B. Arun, C. Nallathambi, A. Pattatheyil, S. Sen
    Clinical Oncology.2020; 32(2): e67.     CrossRef
  • MACC1 expression is an indicator of recurrence in early-stage glottic cancer
    Takuma Makino, Yorihisa Orita, Yuka Gion, Tomoyasu Tachibana, Soshi Takao, Hidenori Marunaka, Kentaro Miki, Naoki Akisada, Yusuke Akagi, Tadashi Yoshino, Kazunori Nishizaki, Yasuharu Sato
    Japanese Journal of Clinical Oncology.2020; 50(4): 392.     CrossRef
  • Is tailored management better than salvage in laryngeal squamous cell carcinomas
    Bhargaw Ilapakruty, Vishal U. S. Rao
    Head & Neck.2020; 42(2): 357.     CrossRef
  • Chemoradiotherapy for high-risk stage II laryngeal cancer
    Satoshi Hamauchi, Tomoya Yokota, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Hirofumi Yasui
    International Journal of Clinical Oncology.2020; 25(9): 1596.     CrossRef
  • Transoral laser microsurgery for glottic cancer in the elderly: Efficacy and safety
    Juan P. Rodrigo, Fabian García‐Velasco, Petra Ambrosch, Vincent Vander Poorten, Carlos Suárez, Andrés Coca‐Pelaz, Primoz Strojan, Kate Hutcheson, Benedikt J. Folz, Manuel Bernal‐Sprekelsen, Alessandra Rinaldo, Carl E. Silver, Alfio Ferlito
    Head & Neck.2019; 41(6): 1816.     CrossRef
  • Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer
    Byung-Hee Kang, Tosol Yu, Jin Ho Kim, Jong Min Park, Jung-In Kim, Eun-Jae Chung, Seong Keun Kwon, Ji-Hoon Kim, Hong-Gyun Wu
    International Journal of Radiation Oncology*Biology*Physics.2019; 105(1): 104.     CrossRef
  • Prognostic factors in patients with T1 glottic cancer treated with radiotherapy
    A. Mucha-Małecka, A. Chrostowska, K. Urbanek, K. Małecki
    Strahlentherapie und Onkologie.2019; 195(9): 792.     CrossRef
  • Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution
    Jeong Won Lee, Jeong Eun Lee, Junhee Park, Jin Ho Sohn, Dongbin Ahn
    Radiation Oncology Journal.2019; 37(2): 82.     CrossRef
  • Outcome of Early-Stage Glottic Laryngeal Carcinoma Patients Treated with Radical Radiotherapy Using Different Techniques
    Oguz Cetinayak, Ersoy Dogan, Ahmet Kuru, Nesrin Akturk, Barbaros Aydin, Cenk Umay, Ilhami Er, Fadime Akman
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature
    Martine Hendriksma, Elisabeth V. Sjögren
    Cancers.2019; 11(9): 1234.     CrossRef
  • Patterns of failure for early-stage glottic carcinoma
    Fatma Sert, Isa Kaya, Kerem Ozturk, Mustafa Esassolak
    Journal of Cancer Research and Therapeutics.2019; 15(3): 576.     CrossRef
  • Oncologic outcomes of KTP laser surgery versus radiation for T1 glottic carcinoma
    Jamal Ahmed, Ahmed Sherif Gabr Ibrahim, Laura M. Freedman, David E. Rosow
    The Laryngoscope.2018; 128(5): 1052.     CrossRef
  • Study design and early result of a phase I study of SABR for early‐stage glottic cancer
    Tosol Yu, Chan Woo Wee, Noorie Choi, Hong‐Gyun Wu, Hyun‐Cheol Kang, Jong Min Park, Jung‐In Kim, Jin Ho Kim, Tack‐Kyun Kwon, Eun‐Jae Chung
    The Laryngoscope.2018; 128(11): 2560.     CrossRef
  • Clinicopathological Characteristics and Survival Rate of Patients with Laryngeal Squamous Cell Carcinoma: A Retrospective Study during 2011–2017 in Yazd, Iran
    Shokouh T Zahir, Koorosh Rahmani, Meisam Mehri, Mohammad Shafiee, Seyed M Reza Mortazavizadeh
    International Journal of Phonosurgery & Laryngology.2018; 8(2): 65.     CrossRef
  • Endoscopic-assisted selective neck dissection via small lateral neck incision for early-stage (T1-2N0M0) head and neck squamous cell carcinoma: 3-year follow-up results
    Faya Liang, Song Fan, Ping Han, Qian Cai, Peiliang Lin, Renhui Chen, Shitong Yu, Xiaoming Huang
    Surgical Endoscopy.2017; 31(2): 894.     CrossRef
  • Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes
    L. Warner, K. Lee, J.J. Homer
    Clinical Otolaryngology.2017; 42(3): 629.     CrossRef
  • Impact of Close and Positive Margins in Transoral Laser Microsurgery for Tis–T2 Glottic Cancer
    Ivana Fiz, Francesco Mazzola, Francesco Fiz, Filippo Marchi, Marta Filauro, Alberto Paderno, Giampiero Parrinello, Cesare Piazza, Giorgio Peretti
    Frontiers in Oncology.2017;[Epub]     CrossRef
  • Volumetric modulated arc radiotherapy of the whole larynx, followed by a single affected vocal cord, for T1a glottic cancer: Dosimetric analysis of a case
    SEUNG-GU YEO
    Molecular and Clinical Oncology.2016; 4(3): 429.     CrossRef
  • 14,389 View
  • 161 Download
  • 38 Web of Science
  • 34 Crossref
Close layer
Tumor Growth Suppression and Enhanced Radioresponse by an Exogenous Epidermal Growth Factor in Mouse Xenograft Models with A431 Cells
Yu Jin Lim, Sang-Rok Jeon, Jae Moon Koh, Hong-Gyun Wu
Cancer Res Treat. 2015;47(4):921-930.   Published online January 7, 2015
DOI: https://doi.org/10.4143/crt.2014.153
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate whether an exogenous epidermal growth factor (EGF) could induce anti-tumor and radiosensitizing effects in vivo.
Materials and Methods
BALB/c-nu mice that were inoculated with A431 (human squamous cell carcinoma) cells in the right hind legs were divided into five groups: I (no treatment), II (EGF for 6 days), III (EGF for 20 days), IV (radiotherapy [RT]), and V (RT plus concomitant EGF). EGF was administered intraperitoneally (5 mg/kg) once a day and the RT dose was 30 Gy in six fractions. Hematoxylin and eosin (H&E) stained sections of tumor, liver, lung, and kidney tissues were investigated. Additionally, tumors were subjected to immunohistochemistry staining with caspase-3.
Results
EGF for 6 days decreased tumor volume, but it approached the level of the control group at the end of follow-up (p=0.550). The duration of tumor shrinkage was prolonged in group V while the slope of tumor re-growth phase was steeper in group IV (p=0.034). EGF for 20 days decreased tumor volume until the end of the observation period (p < 0.001). Immunohistochemistry revealed that mice in group V showed stronger intensity than those in group IV. There were no abnormal histological findings upon H&E staining of the normal organs.
Conclusion
EGF-induced anti-tumor effect was ascertained in the xenograft mouse models with A431 cells. Concomitant use of EGF has the potential role as a radiosensitizer in the design of fractionated irradiation.

Citations

Citations to this article as recorded by  
  • Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox
    Dirk H. Siepe, Lora K. Picton, K. Christopher Garcia
    ACS Synthetic Biology.2023; 12(4): 1081.     CrossRef
  • Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers
    Jae Sik Kim, Joo Ho Lee, Sang-Rok Jeon, Yongsub Kim, Seung Hyuck Jeon, Hong-Gyun Wu
    Cancer Research and Treatment.2023; 55(3): 737.     CrossRef
  • DNA damage alters EGFR signaling and reprograms cellular response via Mre-11
    Yael Volman, Ruth Hefetz, Eithan Galun, Jacob Rachmilewitz
    Scientific Reports.2022;[Epub]     CrossRef
  • Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
    Jiadong Cui, Yan Zhang, Di Su, Tao Li, Yu Li
    Thoracic Cancer.2018; 9(9): 1156.     CrossRef
  • Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand
    Remah Ali, Wells Brown, Stephen Connor Purdy, V. Jo Davisson, Michael K. Wendt
    Cell Death & Disease.2018;[Epub]     CrossRef
  • The paradoxical functions of EGFR during breast cancer progression
    Remah Ali, Michael K Wendt
    Signal Transduction and Targeted Therapy.2017;[Epub]     CrossRef
  • Efficacy of radiotherapy for the treatment of cystic echinococcosis in naturally infected sheep
    Rui Mao, Wen-Bao Zhang, Hong-Zhi Qi, Tao Jiang, Ge Wu, Peng-Fei Lu, Abudula Ainiwaer, Ge Shang, Lin Xu, Jie Hao, Xi Shou, Hai-Tao Li, Jun Li, Song-An Zhang, Yong-Xing Bao, Hao Wen
    Infectious Diseases of Poverty.2017;[Epub]     CrossRef
  • Epidermal Growth Factor Enhances Cellular Uptake of Polystyrene Nanoparticles by Clathrin-Mediated Endocytosis
    Le Phuc, Akiyoshi Taniguchi
    International Journal of Molecular Sciences.2017; 18(6): 1301.     CrossRef
  • 16,076 View
  • 126 Download
  • 9 Web of Science
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP